

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Sihuan Pharmaceutical Holdings Group Ltd.**

**四環醫藥控股集團有限公司**

*(incorporated in Bermuda with limited liability)*

**(Stock code: 0460)**

## **VOLUNTARY ANNOUNCEMENT**

### **BUSINESS UPDATE**

Reference is made to the announcement of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated 30 September 2021 in relation to certain media reports regarding the acquisition (“**Hugel Acquisition**”) of Hugel, Inc (“**Hugel**”) by CBC Group and the potential impact on the Group’s exclusive distribution rights in the People’s Republic of China (the “**PRC**” or “**China**”) of certain products of Hugel.

The board of directors of the Company (the “**Board**”) noted that on 11 February 2022, CBC Group announced that the Hugel Acquisition has been completed, upon which CBC Group has become the single largest shareholder and actual controller of Hugel, controlling approximately 42.90% shareholding in Hugel.

In response to earlier market speculation on the potential impact of the Hugel Acquisition on the cooperation relationship between the Group and Hugel, the management of the CBC Group has agreed with the management of the Group that the Group, as an important and exclusive strategic partner of Hugel in China, CBC Group plans to further promote and strengthen the strategic cooperation between Hugel and the Group in China, which includes, without limitation, their current cooperation in relation to Botulinum Toxin Letybo<sup>®</sup> and Hyaluronic Acid.

The management of the Company, CBC Group and Hugel consider that the continued close strategic collaboration between the Group and Hugel is mutually beneficial to all three parties, and will allow each to maximise value for its respective shareholders. The Company, CBC Group and Hugel are looking forward to, and are confident about, the future collaboration among the three parties, and the Company will work with Hugel and CBC Group towards the goal of making Letybo<sup>®</sup> the No. 1 botulinum toxin brand in the PRC.

The Board also reports that the Group has reached settlement with CBC Group regarding the lawsuit in the PRC.

By Order of the Board  
**Sihuan Pharmaceutical Holdings Group Ltd.**  
**Dr. Che Fengsheng**  
*Chairman and Executive Director*

Hong Kong, 14 February 2022

*As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Mr. Choi Yiau Chong and Ms. Chen Yanling; and the independent non-executive directors of the Company are Mr. Patrick Sun, Mr. Tsang Wah Kwong and Dr. Zhu Xun.*